Breaking News
November 24, 2017 - Video game improves balance in youth with autism
November 24, 2017 - Chromatrap introduces easy-to-use range of DNA kits for molecular biology applications
November 24, 2017 - Bacteria in the intestine can play important pacemaker role in peristalsis
November 24, 2017 - Resistance training promotes environmental quality of life and sense of coherence in older people
November 24, 2017 - Research suggests genome’s spatial organization as important switch for defining cell types
November 24, 2017 - Study highlights need for more clinical trials to improve treatment of children with heart disease
November 24, 2017 - Quickly Treating Mini-Stroke Can Cut Risk for Future Stroke
November 24, 2017 - Inclusion in mainstream school can exacerbate feelings of being ‘different’ in pupils with autism spectrum conditions
November 24, 2017 - Fat-busting ingredients in cinnamon
November 24, 2017 - IMeasureU introduces IMU Step for tracking movements of professional, amateur athletes
November 24, 2017 - Study uncovers key mechanism by which tumors develop resistance to radiation therapy
November 24, 2017 - This Thanksgiving, carve out time for lively discourse on end-of-life wishes
November 24, 2017 - Creutzfeldt-Jakob disease patients harbor infectious prions in their skin
November 24, 2017 - Call for ‘renewed focus’ on deadly threat from antibiotic resistance
November 24, 2017 - 14 signs your daughter may have ADHD
November 24, 2017 - ACA appears to have encouraged more people to use preventive care for heart health
November 23, 2017 - UVA researchers developing new tool to help cancer patients make complex care decisions
November 23, 2017 - SITC releases first consensus recommendations on managing immunotherapy side effects
November 23, 2017 - Research shows major shift in eye surgeries from hospitals to ambulatory surgery centers
November 23, 2017 - Multiple sclerosis drug can beat obstinate bacteria
November 23, 2017 - Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis
November 23, 2017 - Heart disease risk factors linked to walking difficulties in people under age of 78
November 23, 2017 - UVA scientists working to find end-around method to stop triple-negative breast cancer
November 23, 2017 - Researchers develop new tool to share clinico-genomic data
November 23, 2017 - New analysis identifies five distinct patient clusters that may need different approaches to manage asthma
November 23, 2017 - Study shows education and poverty affect outcomes of total knee replacement
November 23, 2017 - Research paves way for development of vaccines against mycoplasma bacteria
November 23, 2017 - Season of festivities can increase opportunities to overindulge in alcohol
November 23, 2017 - Methotrexate drug holiday improves flu vaccine efficacy in rheumatoid arthritis patients
November 23, 2017 - Study identifies signaling pathway essential for growth of new blood vessels
November 23, 2017 - OBD presents results of immunotherapy studies at FNIH Biomarker Consortium Cancer Steering Committee’s annual meeting
November 23, 2017 - New study shows how SNO reaction may contribute to Parkinson’s disease
November 23, 2017 - Study highlights need to improve quality of cardiovascular care for HIV-positive adults
November 23, 2017 - New intelligence tool provides clarity to scientists in booming immuno-oncology field
November 23, 2017 - Cancer Survivors Can Develop PTSD, Too
November 23, 2017 - One step closer toward a treatment for Alzheimer’s disease?
November 23, 2017 - Scientists detect pathological prion protein in skin of CJD patients
November 23, 2017 - Bacterial colonization can function as a pacemaker for the intestine, study reveals
November 23, 2017 - Preclinical study shows clear path toward effective treatment for rare bone disease
November 23, 2017 - Displaced Puerto Ricans face obstacles getting health care
November 23, 2017 - High-intensity exercise improves memory, study finds
November 23, 2017 - Researchers compare shunts and stents to maintain blood flow in infants with heart disease
November 23, 2017 - Gold nanoparticles could potentially help in more effective drug delivery
November 23, 2017 - Moderate coffee consumption more likely to provide beneficial health outcomes
November 23, 2017 - ESMO Consortium Study advocates for equal access to quality cancer treatment across Asia
November 23, 2017 - Gut bacteria at young age can contribute to MS onset and progression, study suggests
November 23, 2017 - Australian government urged to sue tobacco companies
November 23, 2017 - OB/GYN vs PCP: Who Should Handle Sexual Health?
November 23, 2017 - A Teen Mom’s Stress May Harm Her Heart: MedlinePlus Health News
November 23, 2017 - How SORLA protects against Alzheimer’s disease
November 23, 2017 - Newly discovered drug-like compound may revolutionize treatment of autoimmune diseases
November 23, 2017 - Comprehensive review finds increasing number of new heart failure cases in the UK
November 23, 2017 - Leishmania adaptation to environmental changes results from frequent chromosomal amplifications
November 23, 2017 - People who use indoor firing ranges at risk of lead poisoning
November 23, 2017 - Tiny robots could pave way for treating illness in hard-to-reach areas of the body
November 23, 2017 - Study finds smokers wrongly believe Natural American Spirit cigarettes are healthier
November 23, 2017 - Cancer patients willing to swap drug efficacy for reduced risk of adverse events
November 23, 2017 - Oncologists find new biomarker for breast cancer having poor prognosis
November 23, 2017 - Scientists show how diaper phantoms can improve tumor measurements
November 23, 2017 - Metabolites significantly affected in chronic kidney disease, study finds
November 23, 2017 - AR and VR technologies hold potential to increase attractiveness of healthy foods
November 23, 2017 - Amazon Filters offers SupaPore H0P filters for fermentation applications
November 23, 2017 - FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
November 23, 2017 - Does Sex Really Trigger Cardiac Arrest?: MedlinePlus Health News
November 23, 2017 - Baby-boomers and millennials more afflicted by the opioid epidemic
November 23, 2017 - UNC Lineberger professor receives The Leukemia & Lymphoma Society grant for immunotherapy research
November 23, 2017 - Researchers question exclusion of people with prior cancer history from clinical trials
November 23, 2017 - New mechanism in cancer cells to disarm attacking immune cells, study reveals
November 23, 2017 - Most U.S. Parents Can’t Find Good Childcare: Survey
November 23, 2017 - Alpha-fetoprotein (AFP) Test: MedlinePlus Lab Test Information
November 23, 2017 - Opening windows and doors may improve sleep
November 23, 2017 - Research shows how HLF gene affects blood cell development
November 23, 2017 - Deaths due to diabetes higher than expected in Germany
November 23, 2017 - Study finds improvement in men’s health and negative health trend among women
November 23, 2017 - Study finds specific tumor environment that stimulates cancer cells to metastasize
November 23, 2017 - Problems with your hospital care? Speak up!
November 23, 2017 - Thyroid cancer survivors have higher risk for aging-related diseases
November 23, 2017 - Is a common shoulder surgery useless?
November 23, 2017 - Palliative care services help cancer patients
November 23, 2017 - Anti-diabetic drug can enhance repair of UV-induced DNA damage in cells of ‘Moon children’
No Efficacy Hit from Stopping Immunotherapy for AEs

No Efficacy Hit from Stopping Immunotherapy for AEs

image_pdfDownload PDFimage_print

Action Points

  • Efficacy outcomes were similar between patients who discontinued melanoma induction immunotherapy with nivolumab plus ipilimumab due to adverse events (AEs), and those who did not discontinue therapy.
  • Note that these pooled trial data suggest patients may continue to derive benefit even after treatment is stopped because of AEs, and response rate, depth of response, and overall survival do not seem to be diminished for these patients.

Patients who discontinued induction immunotherapy for advanced melanoma because of adverse events did just as well as those who continued treatment uninterrupted, a pooled analysis of randomized trials showed.

Patients who discontinued had an objective response rate of almost 60% compared with about 50% for those who finished induction therapy. Median progression-free survival (PFS) did not differ significantly between patients who discontinued and those who did not; median overall survival had yet to be reached in either group.

“Most patients who discontinued the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did so before receiving all four doses of the combination,” Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues concluded in the Journal of Clinical Oncology.

“Efficacy of nivolumab plus ipilimumab seemed to be similar for those who did and did not discontinue because of adverse events. This suggests that patients may continue to derive benefit from combination therapy even after treatment is stopped because of adverse events.”

Despite the preliminary nature of the data, the findings raised “thought-provoking questions about the possible impact of early treatment cessation in the setting of toxicity on the durability of response,” two Australian oncologists wrote in an accompanying editorial.

“Several key messages ave arisen from this work,” said Matteo S. Carlino, MD, of the University of Sydney, and Shaneen Sandhu, MD, of Peter MacCallum Cancer Center and the University of Melbourne, in the editorial. “The response rate, depth of response, and overall survival do not seem to be diminished for patients who discontinue treatment as a result of immune-related adverse events at induction.

“In addition, the use of immunomodulatory agents to manage checkpoint inhibitor-related toxicities does not seem to hinder responses or durability of responses in the majority of patients who discontinue treatment because of immune-related adverse events at induction. The merits, liability, and optimal duration of ongoing anti-PD-1 therapy after discontinuing induction therapy because of immune-related adverse events will require prospective evaluation.”

The predictive utility of early-onset immune-related adverse events also requires further study, Carlino and Sandhu added.

Clinical trials of combined nivolumab-ipilimumab therapy for advanced melanoma showed that about 40% of patients discontinued induction therapy with the combination because of therapy-related adverse events. Most patients stopped before receiving the recommended four doses of therapy. The impact of early discontinuation on clinical outcomes remained unclear.

To investigate the impact of early discontinuation on outcomes, Postow and colleagues pooled data from randomized phase II and III trials involving a total of 409 patients with advanced melanoma treated with the combination of nivolumab and ipilimumab. Investigators compared treatment efficacy in 96 patients who discontinued treatment during the induction phase of therapy because of adverse events and in 233 patients who did not discontinue because of adverse events.

Investigators evaluated the safety of the combination in patients who discontinued treatment at any time because of adverse events versus those who who did not.

After a minimum follow-up for efficacy of 18 months, median PFS was 8.4 months (95% CI 5.8-16.7) in patients who discontinued induction therapy because of adverse events and 10.8 months (95% CI 5.9-23.0) in those who did not discontinue during induction therapy (P=0.97). The 18-month PFS was 38% in the patients who discontinued and 49% for those who did not. Median PFS had yet to be reached in either group (HR 0.79, 95% CI 0.54-1.17, P=0.2344).

The 18-month overall survival was 67% for patients who discontinued induction therapy because of adverse events and 62% for those who did not.

The objective response rate also did not differ significantly between patients who discontinued because of adverse events (58.3%) and patients who did not (50.2%).

The safety analysis showed that 156 of 407 (38%) patients discontinued treatment at any time because of adverse events, most of which were grade 3/4 severity. Colitis was the most common adverse event leading to discontinuation (10%), followed by elevated liver enzymes (4% to 5%). Colitis also was the most common serious adverse event leading to hospitalization (21% of all patients who discontinued treatment because of adverse events).

The most frequent grade 3/4 treatment-related adverse events associated with discontinuation at any time were gastrointestinal (especially diarrhea and colitis, 20% each). For patients who did not discontinue because of adverse events, the most common grade 3/4 adverse events were hepatic (10%).

Systemic corticosteroids were the most frequently used immunosuppressive therapy for management of adverse events, administered to 91% of patients who discontinued nivolumab-ipilimumab combination therapy because of adverse events and 55% of those who did not discontinue.

The study was supported by Bristol-Myers Squibb and the National Cancer Institute.

Postow disclosed relationships with Bristol-Myers Squibb, Marck, Amgen, Novartis, Array BioPharma, Infinity Pharmaceuticals, and RGenix. All of the coauthors disclosed relationships with one or more healthcare industry company.

Carlino disclosed relationships with Bristol-Myers Squibb, Merck, Amgen, Novartis, and Pierre Fabre. Sandhu disclosed relationships with Merck, Bristol-Myers Squibb, Amgen, and Janssen.


Tagged with:

About author

Related Articles